Therapeutic Effects of Bifidobacterium Longum Kacc 91563 on Dncb-Induced Atopic Dermatitis-Like Skin Lesions in Nc / Nga Mice
Chun-Ho Bae1, Joung-Woon Lee2, Hyun-Ji Park2, Ki-Il Nam2, Ji-Hyun Kim2, Jun-Seol Park2, Si-Hwan Song2
Affiliation
1Aram, Inc., Gyeonggi-do, Republic of Korea
2Chemon, Inc., Gyeonggi-do, Republic of Korea
Corresponding Author
Chul-Kyu Lee, Address: 147, Gwanggyo-ro, Yeongtong-gu, Suwon-si, Gyeonggi- do16229, Republic of Korea, Tel: +82-31-888-6645; E-mail: cklee@chemon.co.kr
Citation
Lee, C.K., et al. Therapeutic Effects of Bifidobacterium Longum Kacc 91563 on Dncb-Induced Atopic Dermatitis-Like Skin Lesions in Nc / Nga Mice. (2018) Int J Food Nutr Sci 5(1): 30- 37.
Copy rights
© 2018 Lee, C.K. This is an Open access article distributed under the terms of Creative Commons Attribution 4.0 International License.
Keywords
Abstract
Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by severe itch. This study was designed to evaluate the therapeutic effects of oral administration of Bifidobacterium longum, KACC 91563 (BLK) on 2, 4-dinitrochlorobenzene (DNCB) - induced AD-like skin lesions in NC / Nga mice. Three doses of BLK (333, 1667, and 3334 mg / kg / day, 7 times a week) were orally administrated to mice with DNCB-induced AD. The therapeutic effect of BLK was assessed by measuring skin AD score, scratching behavior, serum IgE levels, as well as the expression of COX-2, TNF-α, IL-4, IL-10, and IL-12 by immunohistochemistry. AD score, scratching frequency, serum IgE level, COX-2, TNF-α, IL-4, IL-10, and IL-12 increased in mice with DNCB-induced AD. BLK alleviated AD-like symptoms such as skin severity of AD score and scratching behaviors. In addition, BLK reduced IgE, COX-2, and TNF-α, IL-4, IL-10, and IL-12 expression. These results suggest that oral administration of BLK has beneficial therapeutic effects for AD patients.